India, April 24 -- Dyne Therapeutics, Inc. (DYN), Thursday announced that the European Commission has granted orphan drug designation for DYNE-251 for the treatment of Duchenne muscular dystrophy or DMD.
The company added that DYNE-251 is being evaluated in the Phase 1/2 DELIVER global clinical trial in individuals with DMD, who are amenable to exon 51 skipping.
Notably, long-term clinical data from the trial showed unprecedented and sustained functional improvement in the participants at the selected registrational dose.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Following this designation, the company plans to share data from the cohort in late 2025 and expects to move forward with Biologics L...